
Commentary|Articles|March 6, 2015
Augmenting Pre-Operative Risk of Recurrence Stratification in DTC
Author(s)R. Michael Tuttle, MD
R. Michael Tuttle, MD, discusses a study that looked at augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma.
Advertisement
Clinical Pearls
R. Michael Tuttle, MD, professor of medicine, Memorial Sloan Kettering Cancer Center, discusses a study that looked at augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma.
- This study set out to determine if data obtained during pre-operative nodule biopsy could be used to augment risk stratification.
- The ensemble classifier correctly identified 72.4% (21/29) of low risk tumors and 82.6% (43/52) of intermediate/high risk tumors.
- This represents another piece of information to help a physician decide on the proper approach to surgery.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
5



































